ReviewDiagnostics (Basel, Switzerland)2022
The Urinary Microbiome; Axis Crosstalk and Short-Chain Fatty Acid.
Review in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Flupentixol/melitracen for epigastric pain syndrome in female patients with abnormal urinalysis and therapeutic insights into the brain-bladder axis.Scientific reports · 2025Trial
- Urinary volatilomics for biomarker discovery in kidney stone patients and healthy controls.Urolithiasis · 2026Article
- The urinary microbiome, overactive bladder and bladder pain syndrome/interstitial cystitis - mechanisms, diagnostics and therapeutic opportunities.Nature reviews. Urology · 2026Review
- Urinary Microbiome Characteristics in Kidney Transplant Recipients and Their Clinical Implications: A Narrative Review.Annals of transplantation · 2026Review
- Microbiome and metabolomics insights into pediatric urinary tract infection: a narrative review.Childhood kidney diseases · 2026Review
- Characteristics of gut microbiota and metabolites in rats with ketamine-induced cystitis.Scientific reports · 2025Article
- Alterations in urinary microbiota composition in children with overactive bladder: insights from 16S rRNA gene sequencing.Scientific reports · 2025Article
- Review
- From dysbiosis to precision therapy: decoding the gut-bladder axis in bladder carcinogenesis.Frontiers in oncology · 2025Review
- Gut Microbiome Implication and Modulation in the Management of Recurrent Urinary Tract Infection.Pathogens (Basel, Switzerland) · 2024Review
- The role of gut microbiota in prostate inflammation and benign prostatic hyperplasia and its therapeutic implications.Heliyon · 2024Review
- Role of N-acetylkynurenine in mediating the effect of gut microbiota on urinary tract infection: a Mendelian randomization study.Frontiers in microbiology · 2024Article
- Current Viewpoint on Female Urogenital Microbiome-The Cause or the Consequence?Microorganisms · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Our knowledge that "urine is sterile" is no longer accepted after the development of a next-generation sequencing (NGS) test. Using NGS, microbiota in the human body were discovered, and it is expected that this will improve our understanding of human diseases. However, the mechanism involved in the effect of the microbiome on diseases is still poorly understood. Associations of gut microbiome with diseases have been recently reported. Based on such associations, bladder-gut-brain axis, gut-bladder axis, gut-vagina-bladder axis, and gut-kidney axis as novel mechanisms of action of the microbiome have been suggested. Each axis can influence the development and progression of disease through interactions. In these interactions, metabolites of the microbiome including short-chain fatty acids (SCFA) and the inflammasome play an important role. Inflammasomes are multiprotein oligomers that can initiate inflammatory responses. Inflammasomes can trigger inflammation and pyroptosis and ultimately contribute to disease development. SCFAs play an important role in immune cell migration, cytokine production, and maintenance of cellular homeostasis. Associations of inflammasomes with systemic diseases such as obesity and insulin resistance have been reported. The roles of inflammasomes and SCFAs in kidney, bladder, and prostate diseases have also been revealed recently.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.